Novo Nordisk

NOVO-NORDISK AS DKK1 SER'B' (NOVO B)

862,75 DKK 
-3,28% | -29,25 
 14/09/2012 12:47
ISIN DK0060102614 | Actions 

Danemark

Description

Novo Nordisk A/S is a Denmark-based company. It is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company reports two business segments: Diabetes and Biopharmaceuticals. Diabetes division offers a range of diabetes products, including modern insulins, such as NovoRapid, NovoMix and Levemir; new-generation insulins, such as Degludes and DegludecPlus; as well as the FlexTouch insulin pen, among others. Biopharmaceuticals division provides treatments for people with haemophilia, growth hormone deficiency and for women experiencing symptoms of menopause. As of December 31, 2011, the Company marketed its products in more than 190 countries. It reports five geographical regions, namely North America, Europe, Region China, Japan and Korea, as well as International Operations. The Company wholly owns over 70 subsidiaries, such as Novo Nordisk Pharma GmbH, Novo Nordisk Canada Inc., Novo Nordisk Region Japan & Korea A/S, among others.